Nonalcoholic steatohepatitis drug development pipeline: an update

摘要: Nonalcoholic steatohepatitis (NASH) is a burgeoning global health crisis that mirrors the obesity pandemic. This global health crisis has stimulated active research to develop novel NASH pharmacotherapies targeting dysregulated inflammatory, cellular stress, and fibrogenetic processes that include (1) metabolic pathways to improve insulin sensitivity, de novo lipogenesis, and mitochondrial utilization of fatty acids;(2) cellular injury or inflammatory targets that reduce inflammatory cell recruitment and signaling;(3) liver–gut …